guidelines:
  1: International_Prognostic_Index_for_Diffuse_Large_B_cell_Lymphoma_guideline.v1
test_cases:
- id: point 5
  input:
    1:
      gt0003|Age: 66,a
      gt0008|Ann Arbor stage III-IV (III-Involvement on both sides of the diaphragm, IV-Involvement of extranodal sites): 1|local::at0009|Yes|
      gt0009|ECOG performance status ≥2: 1|local::at0012|Yes|
      gt0010|Serum LDH level >1× normal: 1|local::at0015|Yes|
      gt0011|>1 extranodal site (Bone marrow, GI tract, liver, lung, CNS, skin, testes, Waldeyer’s ring): 1|local::at0018|Yes|
  expected_output:
    1:
      gt0013|Age: 1|local::at0006|>60|
      gt0014|Points: 5
      gt0017|R-IPI 4-year overall survival: 55 %
      gt0016|R-IPI Prognosis: Poor
      gt0021|IPI 4-year progression-free survival: 51 %
      gt0018|R-IPI 4-year progression-free survival: 53 %
      gt0019|IPI Risk group: High
      gt0020|IPI 4-year overall survival: 59 %
- id: point 4
  input:
    1:
      gt0003|Age: 66,a
      gt0008|Ann Arbor stage III-IV (III-Involvement on both sides of the diaphragm, IV-Involvement of extranodal sites): 1|local::at0009|Yes|
      gt0009|ECOG performance status ≥2: 1|local::at0012|Yes|
      gt0010|Serum LDH level >1× normal: 1|local::at0015|Yes|
      gt0011|>1 extranodal site (Bone marrow, GI tract, liver, lung, CNS, skin, testes, Waldeyer’s ring): 0|local::at0017|No|
  expected_output:
    1:
      gt0013|Age: 1|local::at0006|>60|
      gt0014|Points: 4
      gt0017|R-IPI 4-year overall survival: 55 %
      gt0016|R-IPI Prognosis: Poor
      gt0021|IPI 4-year progression-free survival: 51 %
      gt0018|R-IPI 4-year progression-free survival: 53 %
      gt0019|IPI Risk group: High
      gt0020|IPI 4-year overall survival: 59 %
- id: point 3
  input:
    1:
      gt0003|Age: 66,a
      gt0008|Ann Arbor stage III-IV (III-Involvement on both sides of the diaphragm, IV-Involvement of extranodal sites): 1|local::at0009|Yes|
      gt0009|ECOG performance status ≥2: 1|local::at0012|Yes|
      gt0010|Serum LDH level >1× normal: 0|local::at0014|No|
      gt0011|>1 extranodal site (Bone marrow, GI tract, liver, lung, CNS, skin, testes, Waldeyer’s ring): 0|local::at0017|No|
  expected_output:
    1:
      gt0013|Age: 1|local::at0006|>60|
      gt0014|Points: 3
      gt0017|R-IPI 4-year overall survival: 55 %
      gt0016|R-IPI Prognosis: Poor
      gt0021|IPI 4-year progression-free survival: 57 %
      gt0018|R-IPI 4-year progression-free survival: 53 %
      gt0019|IPI Risk group: High-intermediate
      gt0020|IPI 4-year overall survival: 49 %
- id: point 2
  input:
    1:
      gt0003|Age: 66,a
      gt0008|Ann Arbor stage III-IV (III-Involvement on both sides of the diaphragm, IV-Involvement of extranodal sites): 1|local::at0009|Yes|
      gt0009|ECOG performance status ≥2: 0|local::at0011|No|
      gt0010|Serum LDH level >1× normal: 0|local::at0014|No|
      gt0011|>1 extranodal site (Bone marrow, GI tract, liver, lung, CNS, skin, testes, Waldeyer’s ring): 0|local::at0017|No|
  expected_output:
    1:
      gt0013|Age: 1|local::at0006|>60|
      gt0014|Points: 2
      gt0017|R-IPI 4-year overall survival: 79 %
      gt0016|R-IPI Prognosis: Good
      gt0021|IPI 4-year progression-free survival: 80 %
      gt0018|R-IPI 4-year progression-free survival: 80 %
      gt0019|IPI Risk group: Low-intermediate
      gt0020|IPI 4-year overall survival: 81 %
- id: point 1
  input:
    1:
      gt0003|Age: 66,a
      gt0008|Ann Arbor stage III-IV (III-Involvement on both sides of the diaphragm, IV-Involvement of extranodal sites): 0|local::at0008|No|
      gt0009|ECOG performance status ≥2: 0|local::at0011|No|
      gt0010|Serum LDH level >1× normal: 0|local::at0014|No|
      gt0011|>1 extranodal site (Bone marrow, GI tract, liver, lung, CNS, skin, testes, Waldeyer’s ring): 0|local::at0017|No|
  expected_output:
    1:
      gt0013|Age: 1|local::at0006|>60|
      gt0014|Points: 1
      gt0017|R-IPI 4-year overall survival: 79 %
      gt0016|R-IPI Prognosis: Good
      gt0021|IPI 4-year progression-free survival: 85 %
      gt0018|R-IPI 4-year progression-free survival: 80 %
      gt0019|IPI Risk group: Low
      gt0020|IPI 4-year overall survival: 82 %
- id: point 0
  input:
    1:
      gt0003|Age: 59,a
      gt0008|Ann Arbor stage III-IV (III-Involvement on both sides of the diaphragm, IV-Involvement of extranodal sites): 0|local::at0008|No|
      gt0009|ECOG performance status ≥2: 0|local::at0011|No|
      gt0010|Serum LDH level >1× normal: 0|local::at0014|No|
      gt0011|>1 extranodal site (Bone marrow, GI tract, liver, lung, CNS, skin, testes, Waldeyer’s ring): 0|local::at0017|No|
  expected_output:
    1:
      gt0013|Age: 0|local::at0005|<=60|
      gt0014|Points: 0
      gt0017|R-IPI 4-year overall survival: 94 %
      gt0016|R-IPI Prognosis: Very good
      gt0021|IPI 4-year progression-free survival: 85 %
      gt0018|R-IPI 4-year progression-free survival: 94 %
      gt0019|IPI Risk group: Low
      gt0020|IPI 4-year overall survival: 82 %
